Stay updated on Tisotumab Vedotin in Cervical Cancer Clinical Trial
Sign up to get notified when there's something new on the Tisotumab Vedotin in Cervical Cancer Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F869ZwVIxrHaQvkLffnpSlN2vnEU.uncropped.jpg&w=3840&q=75)
Latest updates to the Tisotumab Vedotin in Cervical Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 53 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Revision: v2.9.0' has been updated to 'MedlinePlus related topics: Cervical Cancer Drug Information available for: Tisotumab vedotin FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Single arm tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W) Drug : tisotumab vedotin All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity Other Names: TIVDAK'. This change reflects updated information related to the clinical trial on tisotumab vedotin in cervical cancer patients.SummaryDifference99%
Stay in the know with updates to Tisotumab Vedotin in Cervical Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tisotumab Vedotin in Cervical Cancer Clinical Trial page.